Do analysts recommend CVAC or IOVA?

Iovance Biotherapeutics has a consensus price target of $9.11, indicating a potential downside of 10.59%. Given Iovance Biotherapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Iovance Biotherapeutics is more favorable than CureVac. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CureVac 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Iovance Biotherapeutics 2 Sell rating(s) 2 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.45

Do analysts rate RLAY or CVAC?

Relay Therapeutics presently has a consensus price target of $25.92, indicating a potential upside of 43.74%. Given Relay Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Relay Therapeutics is more favorable than CureVac. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Relay Therapeutics 1 Sell rating(s) 1 Hold rating(s) 10 Buy rating(s) 2 Strong Buy rating(s) 2.93 CureVac 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation and earnings, RLAY or CVAC?

CureVac has higher revenue and earnings than Relay Therapeutics. Relay Therapeutics is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Relay Therapeutics $10.35M 381.75 -$276.48M -$1.57 N/A CureVac $70.74M 14.78 $175.50M $0.72 6.47

Do analysts recommend TNGX or CVAC?

Tango Therapeutics currently has a consensus target price of $43.46, suggesting a potential upside of 77.76%. Given Tango Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Tango Therapeutics is more favorable than CureVac. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tango Therapeutics 1 Sell rating(s) 2 Hold rating(s) 13 Buy rating(s) 0 Strong Buy rating(s) 2.75 CureVac 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings and valuation, TNGX or CVAC?

CureVac has higher revenue and earnings than Tango Therapeutics. Tango Therapeutics is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Tango Therapeutics $62.38M 66.09 -$101.59M -$0.85 N/A CureVac $70.74M 14.78 $175.50M $0.72 6.47

Do analysts recommend CVAC or CELC?

Celcuity has a consensus price target of $154.75, suggesting a potential upside of 93.46%. Given Celcuity's stronger consensus rating and higher possible upside, analysts clearly believe Celcuity is more favorable than CureVac. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CureVac 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Celcuity 1 Sell rating(s) 0 Hold rating(s) 11 Buy rating(s) 0 Strong Buy rating(s) 2.83

Which has preferable valuation and earnings, CVAC or CELC?

CureVac has higher revenue and earnings than Celcuity. Celcuity is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CureVac $70.74M 14.78 $175.50M $0.72 6.47 Celcuity N/A N/A -$177.04M -$4.30 N/A

Is CVAC or CELC more profitable?

CureVac has a net margin of 199.92% compared to Celcuity's net margin of 0.00%. CureVac's return on equity of -23.03% beat Celcuity's return on equity. Company Net Margins Return on Equity Return on Assets CureVac 199.92% -23.03% -19.09% Celcuity N/A -350.78% -41.54%

Do analysts rate CVAC or ELVN?

Enliven Therapeutics has a consensus target price of $75.00, suggesting a potential upside of 62.73%. Given Enliven Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Enliven Therapeutics is more favorable than CureVac. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CureVac 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Enliven Therapeutics 1 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.78

CureVac (CVAC) Competitors

$4.66 0.00 (0.00%)

As of 09/22/2026

Compare

CVAC vs. IOVA, RLAY, TNGX, CELC, and ELVN

Should you buy CureVac stock or one of its competitors? CureVac's main competitors and comparable companies include Iovance Biotherapeutics (IOVA), Relay Therapeutics (RLAY), Tango Therapeutics (TNGX), Celcuity (CELC), and Enliven Therapeutics (ELVN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does CureVac compare to Iovance Biotherapeutics?

CureVac (NASDAQ:CVAC) and Iovance Biotherapeutics (NASDAQ:IOVA) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, earnings, profitability, risk, analyst recommendations, valuation, dividends and media sentiment.

17.3% of CureVac shares are held by institutional investors. Comparatively, 77.0% of Iovance Biotherapeutics shares are held by institutional investors. 2.2% of CureVac shares are held by insiders. Comparatively, 7.8% of Iovance Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Iovance Biotherapeutics has a consensus price target of $9.11, indicating a potential downside of 10.59%. Given Iovance Biotherapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Iovance Biotherapeutics is more favorable than CureVac.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CureVac	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Iovance Biotherapeutics	2 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.45

CureVac has a net margin of 199.92% compared to Iovance Biotherapeutics' net margin of -89.11%. CureVac's return on equity of -23.03% beat Iovance Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CureVac	199.92%	-23.03%	-19.09%
Iovance Biotherapeutics	-89.11%	-40.51%	-31.65%

CureVac has a beta of 1.77, suggesting that its share price is 77% more volatile than the broader market. Comparatively, Iovance Biotherapeutics has a beta of 0.83, suggesting that its share price is 17% less volatile than the broader market.

In the previous week, Iovance Biotherapeutics had 13 more articles in the media than CureVac. MarketBeat recorded 13 mentions for Iovance Biotherapeutics and 0 mentions for CureVac. Iovance Biotherapeutics' average media sentiment score of 0.68 beat CureVac's score of 0.00 indicating that Iovance Biotherapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
CureVac	Neutral
Iovance Biotherapeutics	Positive

CureVac has higher earnings, but lower revenue than Iovance Biotherapeutics. Iovance Biotherapeutics is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CureVac	$70.74M	14.78	$175.50M	$0.72	6.47
Iovance Biotherapeutics	$263.50M	17.52	-$390.98M	-$0.73	N/A

Summary

Iovance Biotherapeutics beats CureVac on 9 of the 16 factors compared between the two stocks.

How does CureVac compare to Relay Therapeutics?

Relay Therapeutics (NASDAQ:RLAY) and CureVac (NASDAQ:CVAC) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, valuation, profitability, earnings, media sentiment, institutional ownership and risk.

CureVac has a net margin of 199.92% compared to Relay Therapeutics' net margin of 0.00%. CureVac's return on equity of -23.03% beat Relay Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Relay Therapeutics	N/A	-42.27%	-38.67%
CureVac	199.92%	-23.03%	-19.09%

CureVac has higher revenue and earnings than Relay Therapeutics. Relay Therapeutics is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Relay Therapeutics	$10.35M	381.75	-$276.48M	-$1.57	N/A
CureVac	$70.74M	14.78	$175.50M	$0.72	6.47

97.0% of Relay Therapeutics shares are owned by institutional investors. Comparatively, 17.3% of CureVac shares are owned by institutional investors. 5.0% of Relay Therapeutics shares are owned by company insiders. Comparatively, 2.2% of CureVac shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Relay Therapeutics had 3 more articles in the media than CureVac. MarketBeat recorded 3 mentions for Relay Therapeutics and 0 mentions for CureVac. Relay Therapeutics' average media sentiment score of 0.65 beat CureVac's score of 0.00 indicating that Relay Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Relay Therapeutics	Positive
CureVac	Neutral

Relay Therapeutics has a beta of 1.69, suggesting that its share price is 69% more volatile than the broader market. Comparatively, CureVac has a beta of 1.77, suggesting that its share price is 77% more volatile than the broader market.

Relay Therapeutics presently has a consensus price target of $25.92, indicating a potential upside of 43.74%. Given Relay Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Relay Therapeutics is more favorable than CureVac.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Relay Therapeutics	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.93
CureVac	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Relay Therapeutics beats CureVac on 9 of the 17 factors compared between the two stocks.

How does CureVac compare to Tango Therapeutics?

Tango Therapeutics (NASDAQ:TNGX) and CureVac (NASDAQ:CVAC) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, media sentiment, dividends, analyst recommendations, profitability and earnings.

CureVac has a net margin of 199.92% compared to Tango Therapeutics' net margin of 0.00%. CureVac's return on equity of -23.03% beat Tango Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tango Therapeutics	N/A	-25.75%	-23.36%
CureVac	199.92%	-23.03%	-19.09%

Tango Therapeutics currently has a consensus target price of $43.46, suggesting a potential upside of 77.76%. Given Tango Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Tango Therapeutics is more favorable than CureVac.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tango Therapeutics	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75
CureVac	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Tango Therapeutics has a beta of 1.12, meaning that its stock price is 12% more volatile than the broader market. Comparatively, CureVac has a beta of 1.77, meaning that its stock price is 77% more volatile than the broader market.

CureVac has higher revenue and earnings than Tango Therapeutics. Tango Therapeutics is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tango Therapeutics	$62.38M	66.09	-$101.59M	-$0.85	N/A
CureVac	$70.74M	14.78	$175.50M	$0.72	6.47

In the previous week, Tango Therapeutics had 6 more articles in the media than CureVac. MarketBeat recorded 6 mentions for Tango Therapeutics and 0 mentions for CureVac. Tango Therapeutics' average media sentiment score of 0.89 beat CureVac's score of 0.00 indicating that Tango Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Tango Therapeutics	Positive
CureVac	Neutral

79.0% of Tango Therapeutics shares are held by institutional investors. Comparatively, 17.3% of CureVac shares are held by institutional investors. 6.5% of Tango Therapeutics shares are held by company insiders. Comparatively, 2.2% of CureVac shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Tango Therapeutics and CureVac tied by winning 8 of the 16 factors compared between the two stocks.

How does CureVac compare to Celcuity?

CureVac (NASDAQ:CVAC) and Celcuity (NASDAQ:CELC) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, institutional ownership, earnings, profitability, valuation and risk.

CureVac has a beta of 1.77, meaning that its stock price is 77% more volatile than the broader market. Comparatively, Celcuity has a beta of 0.19, meaning that its stock price is 81% less volatile than the broader market.

CureVac has higher revenue and earnings than Celcuity. Celcuity is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CureVac	$70.74M	14.78	$175.50M	$0.72	6.47
Celcuity	N/A	N/A	-$177.04M	-$4.30	N/A

In the previous week, Celcuity had 6 more articles in the media than CureVac. MarketBeat recorded 6 mentions for Celcuity and 0 mentions for CureVac. Celcuity's average media sentiment score of 0.43 beat CureVac's score of 0.00 indicating that Celcuity is being referred to more favorably in the news media.

Company	Overall Sentiment
CureVac	Neutral
Celcuity	Neutral

17.3% of CureVac shares are held by institutional investors. Comparatively, 63.3% of Celcuity shares are held by institutional investors. 2.2% of CureVac shares are held by insiders. Comparatively, 13.3% of Celcuity shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

CureVac has a net margin of 199.92% compared to Celcuity's net margin of 0.00%. CureVac's return on equity of -23.03% beat Celcuity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CureVac	199.92%	-23.03%	-19.09%
Celcuity	N/A	-350.78%	-41.54%

Celcuity has a consensus price target of $154.75, suggesting a potential upside of 93.46%. Given Celcuity's stronger consensus rating and higher possible upside, analysts clearly believe Celcuity is more favorable than CureVac.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CureVac	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Celcuity	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.83

Summary

CureVac beats Celcuity on 8 of the 15 factors compared between the two stocks.

How does CureVac compare to Enliven Therapeutics?

CureVac (NASDAQ:CVAC) and Enliven Therapeutics (NASDAQ:ELVN) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, risk, dividends, institutional ownership, media sentiment, profitability and analyst recommendations.

17.3% of CureVac shares are held by institutional investors. Comparatively, 95.1% of Enliven Therapeutics shares are held by institutional investors. 2.2% of CureVac shares are held by insiders. Comparatively, 3.0% of Enliven Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Enliven Therapeutics has a consensus target price of $75.00, suggesting a potential upside of 62.73%. Given Enliven Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Enliven Therapeutics is more favorable than CureVac.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CureVac	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Enliven Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.78

CureVac has higher revenue and earnings than Enliven Therapeutics. Enliven Therapeutics is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CureVac	$70.74M	14.78	$175.50M	$0.72	6.47
Enliven Therapeutics	N/A	N/A	-$103.69M	-$1.67	N/A

In the previous week, Enliven Therapeutics had 7 more articles in the media than CureVac. MarketBeat recorded 7 mentions for Enliven Therapeutics and 0 mentions for CureVac. Enliven Therapeutics' average media sentiment score of 0.56 beat CureVac's score of 0.00 indicating that Enliven Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
CureVac	Neutral
Enliven Therapeutics	Positive

CureVac has a net margin of 199.92% compared to Enliven Therapeutics' net margin of 0.00%. Enliven Therapeutics' return on equity of -18.55% beat CureVac's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CureVac	199.92%	-23.03%	-19.09%
Enliven Therapeutics	N/A	-18.55%	-18.09%

CureVac has a beta of 1.77, indicating that its stock price is 77% more volatile than the broader market. Comparatively, Enliven Therapeutics has a beta of 0.3, indicating that its stock price is 70% less volatile than the broader market.

Summary

Enliven Therapeutics beats CureVac on 9 of the 15 factors compared between the two stocks.

Get CureVac News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CVAC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CVAC vs. The Competition

Export

Metric	CureVac	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.05B	$3.98B	$7.31B	$13.29B
Dividend Yield	N/A	3.63%	2.52%	12.57%
P/E Ratio	6.47	13.88	274.02	25.69
Price / Sales	14.78	1,311.41	633.28	76.04
Price / Cash	4.73	113.29	77.80	52.76
Price / Book	1.39	15.30	10.44	6.32
Net Income	$175.50M	-$22.82M	$3.49B	$359.73M
7 Day Performance	N/A	-1.71%	-0.66%	0.17%
1 Month Performance	N/A	-6.17%	-3.16%	-3.27%
1 Year Performance	-13.06%	30.64%	15.15%	5.58%

CureVac Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CVAC CureVac	N/A	$4.66 flat	N/A	N/A	$1.05B	$70.74M	6.47	880
IOVA Iovance Biotherapeutics	1.7139 of 5 stars	$9.20 -0.7%	$8.89 -3.3%	+392.3%	$4.17B	$263.50M	N/A	975
RLAY Relay Therapeutics	2.3771 of 5 stars	$18.88 -0.9%	$25.92 +37.3%	+305.2%	$4.14B	$10.35M	N/A	192
TNGX Tango Therapeutics	2.8296 of 5 stars	$23.95 -2.4%	$43.46 +81.5%	+235.9%	$4.04B	$53.81M	N/A	137
CELC Celcuity	2.7305 of 5 stars	$81.53 -2.4%	$154.55 +89.5%	+52.4%	$3.98B	N/A	N/A	155	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CVAC) was last updated on 9/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CureVac (CVAC) Competitors

CVAC vs. IOVA, RLAY, TNGX, CELC, and ELVN

How does CureVac compare to Iovance Biotherapeutics?

Summary

How does CureVac compare to Relay Therapeutics?

Summary

How does CureVac compare to Tango Therapeutics?

Summary

How does CureVac compare to Celcuity?

Summary

How does CureVac compare to Enliven Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CVAC vs. The Competition

CureVac Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

CureVac (CVAC) Competitors

CVAC vs. IOVA, RLAY, TNGX, CELC, and ELVN

How does CureVac compare to Iovance Biotherapeutics?

Do institutionals and insiders hold more shares of CVAC or IOVA?

Do analysts recommend CVAC or IOVA?

Is CVAC or IOVA more profitable?

Which has more volatility & risk, CVAC or IOVA?

Does the media prefer CVAC or IOVA?

Which has better earnings & valuation, CVAC or IOVA?

Summary

How does CureVac compare to Relay Therapeutics?

Is RLAY or CVAC more profitable?

Which has preferable valuation and earnings, RLAY or CVAC?

Do institutionals & insiders believe in RLAY or CVAC?

Does the media refer more to RLAY or CVAC?

Which has more volatility & risk, RLAY or CVAC?

Do analysts rate RLAY or CVAC?

Summary

How does CureVac compare to Tango Therapeutics?

Is TNGX or CVAC more profitable?

Do analysts recommend TNGX or CVAC?

Which has more risk & volatility, TNGX or CVAC?

Which has better earnings and valuation, TNGX or CVAC?

Does the media favor TNGX or CVAC?

Do insiders & institutionals believe in TNGX or CVAC?

Summary

How does CureVac compare to Celcuity?

Which has more risk & volatility, CVAC or CELC?

Which has preferable valuation and earnings, CVAC or CELC?

Does the media prefer CVAC or CELC?

Do insiders and institutionals hold more shares of CVAC or CELC?

Is CVAC or CELC more profitable?

Do analysts recommend CVAC or CELC?

Summary

How does CureVac compare to Enliven Therapeutics?

Do institutionals & insiders hold more shares of CVAC or ELVN?

Do analysts rate CVAC or ELVN?

Which has better earnings & valuation, CVAC or ELVN?

Does the media prefer CVAC or ELVN?

Is CVAC or ELVN more profitable?

Which has more risk and volatility, CVAC or ELVN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CVAC vs. The Competition

CureVac Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools